J. Pieretti

Severe systemic vasospasm causing recurrent cardiac arrest after orthotopic heart transplantation

pro-apoptotic effects on plasma cells and thus decreases antibody production. In our case, bortezomib has shown efficacy as rescue therapy for recurrent AMR despite the fact that no DSAs have been detected. Beyond the treatment of AMR, bortezomib has also been used in desensitization therapies prior to transplantation. Bortezomib decreases levels of panel reactive antibodies (PRA) in sensitized patients. The patient has continued on a stable outpatient course at 12 months after treatment. The proteasome inhibitor–based therapy with bortezomib appears to be a promising therapeutic option for recurrent AMR.